Gynecologic oncology billing hinges on radical hysterectomy bundling, lymphadenectomy add-ons, and a parallel chemotherapy administration ladder with J-code waste reporting. Add 90-day global periods on radical surgery and prior auth on biologics, and general billers miss revenue on every case. MedFactor delivers gyn-onc-specific RCM that protects every claim.
From ovarian and cervical cancer to complex pelvic surgery, we tailor billing to the coding rules of every gynecologic oncology subspecialty.
Cytoreductive surgery, omentectomy (58943), debulking with lymphadenectomy, and intraperitoneal chemotherapy administration coding.
Radical hysterectomy (58210/58200), pelvic lymph node dissection (38770), and chemoradiation coordination with appropriate bundling.
Total laparoscopic hysterectomy (58570/58571), staging lymphadenectomy, and sentinel node biopsy coding accuracy.
Radical vulvectomy, partial vulvectomy, and inguinal lymphadenectomy with proper staged-procedure modifier 58 usage.
Hydatidiform mole evacuation, low-dose methotrexate chemotherapy tracking, and hCG-based follow-up E/M coding.
Exenterative procedures, urinary diversion, pelvic reconstruction, and modifier 22 for increased procedural service.
Gynecologic oncology uniquely runs two billing tracks in parallel: a radical-surgery base with lymphadenectomy and omental add-ons, and a chemotherapy administration hierarchy (first hour, each additional hour, hydration, non-chemo IV) with J-code drug waste reported separately on JW. This dual-track complexity is the largest source of gyn-onc denials and leakage.
One surgical session bills a radical hysterectomy base with lymph node and omental add-ons, while a separate chemotherapy encounter bills the administration hierarchy with discarded drug waste on the JW modifier.
Gynecologic oncology billing is governed by radical-surgery bundling, the chemo administration hierarchy, and J-code waste rules that general billing companies cannot navigate effectively.
Radical hysterectomy add-ons (lymphadenectomy, omentectomy) dropped or denied as bundled when billed without correct sequencing and modifiers.
96413 first-hour, 96415 add-on hours, and hydration/non-chemo codes mis-sequenced, losing the first-hour base and add-on-hour revenue.
Discarded single-use vial drug waste (JW modifier) not reported, forfeiting reimbursement for wasted chemotherapy units.
Post-operative visits within the 90-day global of radical hysterectomy billed separately and denied, or missed opportunity for modifier 22 complexity.
Same-day E/M with a procedure in the global period denied without modifier 25 supporting a significant, separately identifiable service.
High-cost biologics and chemotherapy agents denied for missing or expired prior authorization, delaying infusion and losing revenue.
Quick reference for the most frequently used codes in gynecologic oncology billing and coding.
| Code | Description | Common Use |
|---|---|---|
| 58210 | Radical abdominal hysterectomy with bilateral pelvic lymphadenectomy | Cervical cancer base surgery |
| 58200 | Radical hysterectomy with pelvic & para-aortic lymphadenectomy | Extended radical surgery |
| 58550 | Laparoscopic-assisted radical hysterectomy | Minimally invasive radical hyst |
| 38530 | Biopsy, lymph node (open) | Lymph node sampling |
| 38770 | Retroperitoneal lymph node dissection | Para-aortic lymphadenectomy add-on |
| 58940 | Resection of ovarian tumor | Ovarian mass / tumor excision |
| 58943 | Omentectomy, total or partial | Ovarian cancer staging |
| 58953 | BSO with omentectomy, total abdominal hysterectomy | Ovarian debulking surgery |
| 96413 | Chemotherapy IV infusion, first hour | Chemo administration base |
| 96415 | Chemotherapy IV infusion, each additional hour | Chemo add-on hour |
| 96521 | Hydration IV infusion, first hour | Pre/post chemo hydration |
| 96365 | IV infusion, non-chemo drug, first hour | Supportive / antiemetic infusion |
| J9170 | Docetaxel 1 mg (HCPCS J-code) | Chemo drug supply |
| Code | Description | Clinical Context |
|---|---|---|
| C53.x | Malignant neoplasm of cervix uteri | Cervical cancer |
| C54.x | Malignant neoplasm of corpus uteri | Endometrial / uterine cancer |
| C56.x | Malignant neoplasm of ovary | Ovarian cancer |
| C51.x | Malignant neoplasm of vulva | Vulvar cancer |
| C52 | Malignant neoplasm of vagina | Vaginal cancer |
| C58 | Malignant neoplasm of placenta | Gestational trophoblastic |
| D07.x | Carcinoma in situ of cervix / endometrium | Pre-invasive CIN / FIGO 0 |
| Z51.11 | Encounter for antineoplastic chemotherapy | Chemo encounter |
| Z12.72 | Encounter for screening for malignant neoplasm of ovary | BRCA / high-risk screening |
| Z85.42 | Personal history of malignant neoplasm of ovary | Surveillance follow-up |
| Modifier | Description | Gyn-Onc Application |
|---|---|---|
| 25 | Separate E/M same day | E/M with same-day procedure in global period |
| 50 | Bilateral procedure | Bilateral lymph node dissection, BSO |
| 51 | Multiple procedures | BSO with radical hysterectomy same session |
| 59 | Distinct procedural service | Distinct lymph node / omental procedures same session |
| 22 | Increased procedural service | Unusually complex radical surgery / exenteration |
| 26 | Professional component | Radiation / imaging interpretation |
| TC | Technical component | Imaging / facility technical portion |
| JW | Discarded drug waste | Discarded single-use chemo vial waste |
Comprehensive revenue cycle management designed specifically for gynecologic oncology practices.
Specialty coders handle radical hysterectomy bundling, lymphadenectomy add-ons, chemo administration hierarchy, and JW waste reporting with accuracy.
Surgery bundling defense, chemo administration hierarchy corrections, and J-code waste appeals with procedural documentation for gyn-onc denials.
Pre-infusion authorization for high-cost biologics, chemotherapy agents, and complex radical surgery procedures.
Prioritized follow-up on aged radical surgery, chemotherapy, and J-code claims with strategic payer escalation to maximize recovery.
Regular audits focused on chemo administration capture, JW waste reporting, modifier 25/51/59, and 90-day global-period compliance.
Real-time dashboards tracking radical-surgery volume, chemo administration units, and J-code waste capture by payer.
Understanding the most common denial reasons is the first step to preventing them on radical surgery, chemotherapy, and J-code claims.
Lymphadenectomy and omentectomy denied as bundled into radical hysterectomy when billed without correct sequencing and modifiers.
Add-on sequencing with modifier 51/59 for distinct procedures same session.
96413 first-hour base and 96415 add-on hours mis-sequenced, losing the first-hour and additional-hour revenue.
Correct administration ladder with 96413 base, 96415 add-on hours, and hydration/non-chemo separation.
Discarded single-use vial waste not reported on the JW modifier, forfeiting reimbursement for wasted chemo units.
JW modifier reporting on every discarded unit with documented waste log.
High-cost biologics and chemotherapy agents denied for missing or expired prior authorization.
Pre-infusion prior auth verification with payer-specific criteria tracking.
Identifying and plugging these common revenue leakage points can significantly improve your practice's bottom line.
Lymphadenectomy and omentectomy not billed as add-ons to radical hysterectomy.
96415 additional-hour infusions not billed when the first-hour 96413 is captured.
Discarded single-use vial waste not reported, losing reimbursement on wasted chemo units.
Modifier 22 for unusually complex radical surgery not applied, losing complexity-based revenue.
See how gyn-onc-specific revenue cycle management transforms your practice's financial performance.
A structured onboarding process designed to deliver measurable improvements within the first 90 days.
Review of gyn-onc billing operations, surgery add-on capture, chemo administration, and revenue cycle baseline.
EMR and infusion-system integration, dedicated gyn-onc billing team, and payer enrollment verification.
Full billing with real-time claim submission, modifier verification, and denial prevention protocols.
Performance review against baseline, workflow optimization, and documented revenue improvement.
How our gyn-onc-specific approach compares to in-house billing and general medical billing companies.
| Capability | In-House Team | General Billing Co. | MedFactor Gyn-Onc |
|---|---|---|---|
| Radical surgery add-on capture | Inconsistent | ✕ | ✓ |
| Chemo administration hierarchy (96413/96415) | ✕ | ✕ | ✓ |
| J-code waste (JW) reporting | ✕ | ✕ | ✓ |
| 90-day global-period tracking | Manual | Partial | ✓ |
| Modifier 25 with global procedures | Inconsistent | Partial | ✓ |
| Biologic / chemo prior auth | Manual | Partial | ✓ |
| Modifier 22 for complex surgery | ✕ | ✕ | ✓ |
| Chemo unit & J-code waste reporting | ✕ | ✕ | ✓ |
| Dedicated gyn-onc billing team | ✕ | ✕ | ✓ |
Our team combines deep gynecologic oncology billing expertise with the technology and processes to deliver consistent, measurable results for ovarian, cervical, and endometrial cancer programs.
Discover exactly where your gynecologic oncology practice is losing revenue. Our no-obligation audit analyzes your surgery add-on capture, chemo administration hierarchy, and J-code waste reporting.
Real results from gynecologic oncology practices that partnered with MedFactor for specialty revenue cycle management.
An ovarian-cancer surgery + chemotherapy practice was dropping lymphadenectomy add-ons and mis-sequencing the chemo administration ladder. MedFactor implemented add-on sequencing and the 96413/96415 hierarchy, recovering substantial revenue in eight months.
A cervical-cancer group was not reporting discarded single-use vial waste on the JW modifier and losing reimbursement on wasted chemo units. MedFactor implemented JW reporting protocols, recovering waste-based revenue per quarter.
An endometrial surgery center was missing modifier 22 for complex radical hysterectomy and billing global-period visits separately. MedFactor implemented complexity-based modifier protocols that protected surgical and follow-up revenue.
No matter where your gynecologic oncology practice operates, our team understands the payer landscape and regulatory requirements in your region.
Deep coding knowledge across Medicare, Medicaid, and all major commercial payers for gyn-onc services.
96413/96415 hierarchy and JW waste reporting applied correctly across all 50 states and payer policies.
Facility and professional billing coordination across hospital-based radical surgery and infusion suites.
State-by-state prior authorization requirements for high-cost biologics and chemotherapy agents.
Common questions from gynecologic oncology practices considering MedFactor's specialty RCM services.
Radical hysterectomy is billed as one base procedure code plus add-on codes for distinct work performed in the same session. For cervical cancer, 58210 (radical abdominal hysterectomy with bilateral pelvic lymphadenectomy) or 58200 (with para-aortic lymphadenectomy) is the base, with 38770 (retroperitoneal lymph node dissection) and 58943 (omentectomy) as add-ons, and bilateral salpingo-oophorectomy (58953 components) billed with modifier 51 where the payer requires it. We sequence the highest-valued radical surgery code as the base, add each distinct procedure with the correct add-on code, and apply modifier 51 or 59 for legitimately separate procedures — preventing NCCI bundling denials while capturing every component of the surgical session.
Pelvic lymphadenectomy is included in the radical hysterectomy base codes 58210 and 58200, so it is not billed separately when performed as part of those procedures. However, para-aortic retroperitoneal lymph node dissection (38770) is billed as an add-on when performed in addition to the pelvic dissection, and open lymph node biopsy (38530) is billed when only a sampling is performed. We verify NCCI edits before submission so lymphadenectomy is coded at the correct level — included in the base when bundled, add-on when extended, and distinct when sampled — preserving the legitimate lymph-node revenue without triggering bundling denials.
Chemotherapy IV infusion is billed as a hierarchy: 96413 (chemotherapy administration, intravenous infusion, first hour) is the base, and 96415 (each additional hour) is billed for every hour of infusion beyond the first. Hydration is billed separately with 96521 (first hour) when it is the primary service, and non-chemo drug IV infusion uses 96365 (first hour) for supportive agents such as antiemetics. The chemotherapy administration code must be sequenced first when chemo is the primary reason for the encounter. We bill the 96413 first-hour base on every chemo infusion, add 96415 for each additional hour, separate hydration and non-chemo infusions with the correct codes, and append the proper J-code for the drug supply — so every administration hour and every drug unit is captured.
When a single-use vial of a chemotherapy drug is partially administered and the remainder is discarded, the discarded portion is reported on a separate claim line with the JW (discarded drug) modifier, while the administered portion is billed on its own line with the J-code for the drug (for example J9170 for docetaxel). Medicare and most payers require JW reporting for any discarded amount from a single-use vial so the practice is reimbursed for the wasted units. We log every discarded unit, report it on the JW modifier line with the drug J-code, and keep the waste documentation the payer requires — recovering revenue that most practices lose by billing only the administered dose.
Radical hysterectomy (58200/58210) carries a 90-day global period, meaning all routine post-operative visits and related care are bundled into the surgical payment and cannot be billed separately. To capture legitimate additional revenue we track the global period in the practice management system, document modifier 22 (increased procedural service) when the radical surgery is unusually complex — such as extensive adhesions, exenteration, or reconstruction — and bill only services that are genuinely unrelated or staged with the correct modifier (58 for staged, 78 for unplanned return). We do not bill routine global follow-up separately, and we ensure every legitimately billable out-of-global service is captured with the right modifier.
Modifier 25 is appended to an E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as a procedure — for example a pre-operative assessment or a separately documented decision-making visit on the day of a minor procedure or an infusion. Within a 90-day global period, modifier 25 only supports an E/M that is unrelated to the global surgery, so we document the medical necessity and the separate nature of the visit. Without modifier 25, the same-day E/M is denied as bundled into the procedure; without supporting documentation, the modifier 25 claim is denied on audit. We pair every modifier 25 with the supporting note so the E/M is paid rather than denied.
MedFactor applies the same code-level precision across the full practice spectrum. See how we bill these related specialties.
CPT®, ICD-10, HCPCS, and modifier codes referenced on this page reflect the current code sets and are subject to annual updates — always verify against the current-year fee schedule before submission. KPIs and case-study figures shown are representative benchmarks, not guarantees of individual practice results.
Your gyn-onc practice deserves billing partners who know radical hysterectomy add-on coding, the 96413/96415 administration hierarchy, and JW waste reporting — and code every claim correctly. Let MedFactor show you what specialty RCM can do.